Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4163-4166

  Ferran, Aude ^a   Dupouy, Véronique ^a   Toutain, Pierre Louis ^a   Bousquet Mélou, Alain ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MARBOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MUTATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; ESCHERICHIA COLI; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; MUTANT SELECTION WINDOW; NONHUMAN; POPULATION SIZE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL VIABILITY; MUTATION; QUINOLONES; TIME FACTORS;

EID: 35848959765     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00156-07     Document Type: Article

References (10)

1. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
2. Dong, Y., X. Zhao, B. N. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44: 2581-2584.
3. Firsov, A. A., D. Savarino, M. Ruble, D. Gilbert, B. Manzano, A. A. Medeiros, and S. H. Zinner. 1996. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob. Agents Chemother. 40:734-738.
4. Firsov, A. A., S. N. Vostrov, O. V. Kononenko, S. H. Zinner, and Y. A. Portnoy. 1999. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 43:498-502.
5. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
6. Komp Lindgren, P., Å. Karlsson, and D. Hughes. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47:3222-3232.
7. Marcusson, L. L., S. K. Olofsson, P. Komp Lindgren, O. Cars, and D. Hughes. 2005. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J. Antimicrob. Chemother. 55: 938-943.
8. Olofsson, S. K., L. L. Marcusson, P. Komp Lindgren, D. Hughes, and O. Cars. 2006. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57:1116-1121.
9. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
10. Zinner, S. H., I. Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency, and bacterial killing. J. Antimicrob. Chemother. 52: 616-622.